Literature DB >> 26438681

A case of donepezil-related torsades de pointes.

Jamie Kitt1, Robert Irons2, Mohamed Al-Obaidi1, Constantinos Missouris1.   

Abstract

An 80-year-old woman with Alzheimer's dementia presented with diarrhoea, vomiting and worsening confusion following an increase in donepezil dose from 5 to 10 mg. The ECG revealed prolongation of QTc interval. Soon after admission, she became unresponsive with polymorphic ventricular tachycardia (VT). Cardiopulmonary resuscitation with a 200 J shock was successful in establishing cardiac output. Following the discontinuation of donepezil, the QTc interval normalised and no further arrhythmias were recorded. Treatment with anticholinesterase inhibitors may result in life-threatening VT. Vigilance is required for the identification of this condition in patients presenting with presyncope, syncope or seizures. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26438681      PMCID: PMC4600768          DOI: 10.1136/bcr-2015-211900

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  3 in total

1.  Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

Authors:  Bengt Winblad; Lena Kilander; Sture Eriksson; Lennart Minthon; Stellan Båtsman; Anna-Lena Wetterholm; Catarina Jansson-Blixt; Anders Haglund
Journal:  Lancet       Date:  2006-04-01       Impact factor: 79.321

2.  Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and Torsade de Pointes.

Authors:  Atsushi Tanaka; Shoichi Koga; Yoshihiro Hiramatsu
Journal:  Intern Med       Date:  2009-07-15       Impact factor: 1.271

3.  Torsades de Pointes with QT prolongation related to donepezil use.

Authors:  Tomofumi Takaya; Masashi Okamoto; Keiko Yodoi; Katsuya Hata; Yoichi Kijima; Hideto Nakajima; Yuji Nishikawa; Tomoyuki Kita; Mitsuaki Ito; Toshihiko Seo; Seinosuke Kawashima
Journal:  J Cardiol       Date:  2009-05-07       Impact factor: 3.159

  3 in total
  8 in total

Review 1.  Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.

Authors:  Galia Jackobson; Narin Nard Carmel; Dor Lotan; Anjelika Kremer; Dan Justo
Journal:  Z Gerontol Geriatr       Date:  2016-11-22       Impact factor: 1.281

2.  Lesson of the month 1: Prolonged QT syndrome due to donepezil: a reversible cause of falls?

Authors:  Emily G Jackson; Sarah Stowe
Journal:  Clin Med (Lond)       Date:  2019-01       Impact factor: 2.659

Review 3.  Synthesis of Biologically Active Molecules through Multicomponent Reactions.

Authors:  Daniel Insuasty; Juan Castillo; Diana Becerra; Hugo Rojas; Rodrigo Abonia
Journal:  Molecules       Date:  2020-01-24       Impact factor: 4.411

4.  QT interval prolongation and Torsades de Pointes with donepezil, rivastigmine and galantamine.

Authors:  Katie Malone; Jules C Hancox
Journal:  Ther Adv Drug Saf       Date:  2020-08-17

5.  Donepezil-induced QTc prolongation: A case report.

Authors:  Samantha M Vogel; Lisa M Mican; Tawny L Smith
Journal:  Ment Health Clin       Date:  2019-05-10

Review 6.  Correlation Between Donepezil and QTc Prolongation and Torsades de Pointes: A Very Rare Phenomenon.

Authors:  Bilal Haider Malik; Pousette Hamid; Safeera Khan; Deepti Gupta; Muhammad Islam
Journal:  Cureus       Date:  2019-12-23

7.  Synthesis, and molecular modeling of bis(3-(piperazine-1-yl)propyl)tungstate (BPPT) nanoparticles, and its first catalytic application for one-pot synthesis of 4H-chromene derivatives.

Authors:  Khalil Eskandari; Yaghoub Pourshojaei; Fatemeh Haghani; Mahnaz Shabani; Ali Asadipour
Journal:  Heliyon       Date:  2019-09-13

Review 8.  QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson's Disease Psychosis: A Narrative Review.

Authors:  Yasar Torres-Yaghi; Amelia Carwin; Jacob Carolan; Steven Nakano; Fahd Amjad; Fernando Pagan
Journal:  Neuropsychiatr Dis Treat       Date:  2021-12-24       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.